Trial · NCT07879885
An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT07879885, Phase 2, Recruiting, Hansoh BioMedical R&D Company
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis. Trials, record NCT07879885. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07879885
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis
- NCT number
- NCT07879885
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 390 participants, estimated
- Lead sponsor
- Hansoh BioMedical R&D Company
- Conditions
- Moderate-to-severe Plaque Psoriasis
- Interventions
- HS-20137
- First posted
- 2026-10-19
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants with Adverse Events | up to 20 weeks | Adverse events will be assessed for incidence, severity, relationship to study intervention, duration, and outcome. |
| Primary | Changes From Baseline in Clinical Laboratory Test Results | Frame: up to 20 weeks | Changes from baseline in protocol-specified clinical laboratory test results following administration of HS-20137 will be assessed. |
| Primary | Changes From Baseline in Physical Examination Findings | up to 20 weeks | Changes from baseline in physical examination findings following administration of HS-20137 will be assessed. |
| Primary | Changes From Baseline in Vital Signs | up to 20 weeks | Changes from baseline in protocol-specified vital signs following administration of HS-20137 will be assessed. |
| Primary | Incidence of Clinically Significant Electrocardiogram (ECG) Abnormalities | up to 20 weeks | The incidence of clinically significant electrocardiogram (ECG) abnormalities following administration of HS-20137 will be assessed. |
| Secondary | PASI 50, PASI 75, PASI 90, and PASI 100 Response Rates at Each Visit Time Point | up to 20 weeks | The Psoriasis Area and Severity Index (PASI) is a scoring system used to assess the severity of psoriasis based on lesion severity and area of involvement. PASI 50, PASI 75, PASI 90, and PASI 100 response rates are defined as the percentages of participants achieving at least 50%, 75%, 90%, and 100% reduction, respectively, in PASI score from baseline. These response rates will be assessed at each visit time point. |
| Secondary | PASI Scores and Changes From Baseline at Each Visit Time Point | up to 20 weeks | The Psoriasis Area and Severity Index (PASI) score and changes from baseline in PASI score will be assessed at each visit time point. |
| Secondary | sPGA 0/1 Response Rate at Each Visit Time Point | up to 20 weeks | The static Physician's Global Assessment (sPGA) is a 5-point scale ranging from 0 (clear) to 4 (severe) used to assess the overall severity of psoriasis lesions. The sPGA 0/1 response rate is defined as the percentage of participants achieving an sPGA score of 0 (clear) or 1 (almost clear) at each visit time point. |
| Secondary | sPGA 0 Response Rate at Each Visit Time Point | up to 20 weeks | The static Physician's Global Assessment (sPGA) is a 5-point scale ranging from 0 (clear) to 4 (severe) used to assess the overall severity of psoriasis lesions. The sPGA 0 response rate is defined as the percentage of participants achieving an sPGA score of 0 (clear) at each visit time point. |
| Secondary | BSA Scores and Changes From Baseline at Each Visit Time Point | up to 20 weeks | The percentage of body surface area (BSA) affected by psoriasis and changes from baseline in BSA will be assessed at each visit time point. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07879885
GET https://conductscience.org/api/trials/v1/NCT07879885/registered